Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Swift who wrote (2534)	4/25/1999 2:53:00 PM
From: rkrw	Read Replies (2) of 10280

I own shares in FRX. I believe they can earn $2 a share this fiscal year, so a PE of closer to 24, not over 100. Celexa has been doing great. Their single isomer version is in Phase III. I am unclear on what the arrangement with WLA will be for it. On a related note, it does show how an SSRI with a more modest side effect profile can break into the market. Hopefully the single isomer version of prozac will stack up well against celexa and racemic prozac. The Sepracor annual report arrived on Friday. In case anyone missed it, two new drugs listed, including Serevant, which is the world's leading drug (brand sales) for asthma with $700M in 1998 sales. Another potential coup and a logical licensing candidate for Glaxo.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next